Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c

BACKGROUND: The EGFR tyrosine kinase inhibitor gefitinib is used in therapy for non-small-cell lung cancer (NSCLC). However, its application is limited by resistance-accelerated disease progression, which is accompanied by the epithelial-to-mesenchymal transition (EMT). In the present study, we perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Narita, Michiko, Shimura, Eri, Nagasawa, Atsumi, Aiuchi, Toshiki, Suda, Yukari, Hamada, Yusuke, Ikegami, Daigo, Iwasawa, Chizuru, Arakawa, Kazuhiko, Igarashi, Katsuhide, Kuzumaki, Naoko, Yoshioka, Yusuke, Ochiya, Takahiro, Takeshima, Hideyuki, Ushijima, Toshikazu, Narita, Minoru
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2017
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321411/
https://www.ncbi.nlm.nih.gov/pubmed/28225782
http://dx.doi.org/10.1371/journal.pone.0172115

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5321411/
https://www.ncbi.nlm.nih.gov/pubmed/28225782
http://dx.doi.org/10.1371/journal.pone.0172115

Ejemplares similares